R Zarate

Summary

Affiliation: University of Navarra
Country: Spain

Publications

  1. ncbi request reprint Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients
    R Zárate Romero
    Laboratory of Biotechnology and Pharmacogenomics, Center for Applied Medical Research, University Clinic of Navarra, Navarra 31008, Spain
    Oncol Rep 16:497-503. 2006
  2. ncbi request reprint Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy
    R N Zárate
    Laboratory of Biotechnology and Pharmacogenomics, University Clinic of Navarra, Pamplona 31008, Spain
    World J Gastroenterol 12:6032-6. 2006
  3. ncbi request reprint GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment
    R Zarate
    Laboratory of Biotechnology, University Clinic of Navarra, Pamplona, Spain
    Curr Drug Metab 8:481-6. 2007
  4. doi request reprint A new mutation in the hMSH2 gene in a Spanish Lynch syndrome family
    Ruth Zarate
    Clinical Genetics Unit, University Clinic of Navarra, Pamplona, Navarra, Spain
    Clin Transl Oncol 12:849-51. 2010
  5. pmc Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    Laboratory of Pharmacogenomics, Division of Oncology, CIMA, University Clinic of Navarra, Avda Pio XII 36, Pamplona, Spain
    Br J Cancer 102:987-94. 2010
  6. pmc Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Br J Cancer 103:1529-35. 2010
  7. doi request reprint Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy
    J Rodriguez
    Department of Oncology, Clinic University of Navarra, Pamplona, Spain
    Eur J Cancer 47:839-47. 2011
  8. pmc Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Br J Cancer 107:287-90. 2012
  9. doi request reprint Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions
    N Ramirez
    Laboratory of Pharmacogenomics, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Eur J Cancer 44:2689-95. 2008
  10. ncbi request reprint Combining chemotherapy and targeted therapies in metastatic colorectal cancer
    J Rodriguez
    Unit for the Research and Treatment of Gastrointestinal Malignancies, Department of Oncology, Clinica Universitaria, Center for Applied Medical Research, University of Navarra, Spain
    World J Gastroenterol 13:5867-76. 2007

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients
    R Zárate Romero
    Laboratory of Biotechnology and Pharmacogenomics, Center for Applied Medical Research, University Clinic of Navarra, Navarra 31008, Spain
    Oncol Rep 16:497-503. 2006
    ..Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen...
  2. ncbi request reprint Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy
    R N Zárate
    Laboratory of Biotechnology and Pharmacogenomics, University Clinic of Navarra, Pamplona 31008, Spain
    World J Gastroenterol 12:6032-6. 2006
    ..To evaluate the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemo-radiotherapy in patients with resected gastric cancer...
  3. ncbi request reprint GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment
    R Zarate
    Laboratory of Biotechnology, University Clinic of Navarra, Pamplona, Spain
    Curr Drug Metab 8:481-6. 2007
    ..3 to 254), P = 0.008. Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline-based treatment of breast cancer...
  4. doi request reprint A new mutation in the hMSH2 gene in a Spanish Lynch syndrome family
    Ruth Zarate
    Clinical Genetics Unit, University Clinic of Navarra, Pamplona, Navarra, Spain
    Clin Transl Oncol 12:849-51. 2010
    ..The mutation was not present in 116 normal controls screened. The medical implications for the carrier relatives are discussed...
  5. pmc Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    Laboratory of Pharmacogenomics, Division of Oncology, CIMA, University Clinic of Navarra, Avda Pio XII 36, Pamplona, Spain
    Br J Cancer 102:987-94. 2010
    ..A pharmacogenomic analysis was performed to investigate the association between SNPs and treatment outcome...
  6. pmc Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Br J Cancer 103:1529-35. 2010
    ..Pharmacogenomic analysis was performed to investigate the association between VEGF single-nucleotide polymorphisms and clinical outcome...
  7. doi request reprint Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy
    J Rodriguez
    Department of Oncology, Clinic University of Navarra, Pamplona, Spain
    Eur J Cancer 47:839-47. 2011
    ..To investigate whether single nucleotide polymorphisms (SNPs) in gemcitabine (GMB) metabolism genes were associated with clinical outcome in pre-treated metastatic colorectal cancer (mCRC) patients...
  8. pmc Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
    A Abajo
    Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Br J Cancer 107:287-90. 2012
    ..To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients...
  9. doi request reprint Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions
    N Ramirez
    Laboratory of Pharmacogenomics, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Eur J Cancer 44:2689-95. 2008
    ..Our results indicate that epigenetic changes in mucosa surrounding colorectal neoplastic lesions may describe a 'field cancerisation' phenomenon that may occur previous to genetic alterations in early stages of carcinogenesis...
  10. ncbi request reprint Combining chemotherapy and targeted therapies in metastatic colorectal cancer
    J Rodriguez
    Unit for the Research and Treatment of Gastrointestinal Malignancies, Department of Oncology, Clinica Universitaria, Center for Applied Medical Research, University of Navarra, Spain
    World J Gastroenterol 13:5867-76. 2007
    ..In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer...
  11. pmc Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues
    E Bandres
    Laboratory of Pharmacogenomics, Cancer Research Program Center for Applied Medical Research, University of Navarra, Navarra, Spain
    Mol Cancer 5:29. 2006
    ..In addition, the expression level of miR-31 was correlated with the stage of CRC tumor. Our results suggest that miRNA expression profile could have relevance to the biological and clinical behavior of colorectal neoplasia...